title: Current management and novel agents for malignant melanoma.
abstract: Advanced malignant melanoma remains a challenging cancer. Over the past year, there have been 3 agents approved for treatment of melanoma by Food and Drug Administration. These include pegylated interferon alpha-2b for stage III melanoma, vemurafenib for unresectable or metastatic melanoma with BRAF V600E mutation, and ipilimumab for treatment of unresectable or metastatic melanoma. This review will also update on the development of novel agents, including tyrosine kinase inhibitors and adoptive cellular therapy.
authors.affiliation: Division of Hematology and Oncology, New York Medical College and Westchester Medical Center, Valhalla, New York 10595, USA.
authors.forename: Byung
authors.initials: B
authors.lastname: Lee
authors.forename: Nikhil
authors.initials: N
authors.lastname: Mukhi
authors.forename: Delong
authors.initials: D
authors.lastname: Liu
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents